Inozyme Pharma Announces Positive Interim Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ENPP1 Deficiency and ABCC6 Deficiency (PXE) by Seini Moimoi | Sep 26, 2023 | Portfolio News
Patients Receiving Somatus Transitions of Care Assessment Services 49% Less Likely to Experience Hospital Readmission by Seini Moimoi | Sep 26, 2023 | Portfolio News
89bio Announces U.S. FDA has Granted Breakthrough Therapy Designation for Pegozafermin in Nonalcoholic Steatohepatitis (NASH) by Seini Moimoi | Sep 21, 2023 | Portfolio News
FDA Approves LimFlow System in Patients with Chronic Limb-Threatening Ischemia and No Suitable Endovascular or Surgical Revasucularization Options by Seini Moimoi | Sep 12, 2023 | Portfolio News
Mirum Pharmaceuticals Announces the Appointment of Eric Bjerkholt as Chief Financial Officer by Seini Moimoi | Sep 11, 2023 | Portfolio News
CG Oncology Announces Key Executive Appointments in Commercialization, Medical and Manufacturing Operations by Seini Moimoi | Sep 5, 2023 | Portfolio News
Mirum Pharmaceuticals Completes Acquisition of Bile Acid Product Portfolio for Treatment of Rare Liver Diseases from Travere Therapeutics by Seini Moimoi | Sep 5, 2023 | Portfolio News
Zenas BioPharma Announces Strategic License and Collaboration Agreement with Bristol Myers Squibb by Seini Moimoi | Sep 5, 2023 | Portfolio News
CG Oncology Announces $105 Million Oversubscribed Crossover Financing to Support Continued Advancement of Clinical-Stage Bladder Cancer Pipeline by Seini Moimoi | Aug 2, 2023 | Portfolio News
CG Oncology Announces $105 Million Oversubscribed Crossover Financing to Advance Clinical-Stage Bladder Cancer Pipeline by Seini Moimoi | Aug 2, 2023 | Uncategorized
